In this issue:
- Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer
- Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma
- Perioperative nivolumab in resectable lung cancer
- Consolidation durvalumab for limited-stage SCLC
- Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
- Association of pretreatment emotional distress with ICI response in NSCLC
- ICIs beyond progression with prior immunotherapy in driver gene-negative advanced NSCLC
- Extending nivolumab dosing intervals
- ICI-associated CV adverse events
- Initiating immunotherapy for metastatic cancer at the end-of-life
Please login below to download this issue (PDF)